Jefferies Downgrades Immunogen Inc. (IMGN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Immunogen (IMGN) PT Cut to $9 at Cantor Fitzgerald
December 22, 2014 7:50 AM ESTCantor Fitzgerald analyst Mara Goldstein reiterated a Hold rating and lowered her price target on Immunogen Inc. (NASDAQ: IMGN) price target of $9.00 (from $14.00) on disappointing MARIANNE news.
Goldstein said Friday's 40% sell-off have been an overreaction but they remain on the sidelines. "The... More
Leerink Swann Downgrades Immunogen Inc. (IMGN) to Market Perform
December 19, 2014 1:36 PM ESTLeerink Swann downgraded Immunogen Inc. (NASDAQ: IMGN) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $10.85 yesterday.
... MoreImmunogen (IMGN) PT to $10 at Credit Suisse on Disappointing MARIANNE Trial Results
December 19, 2014 9:32 AM ESTCredit Suisse analyst Jason Kantor cut estimates and his price target on Neutral-rated Immunogen Inc. (NASDAQ: IMGN) to $10.00 (from $14.00) following disappoint MARIANNE data.
Kantor said investors largely assumed the data would be positive and Kadcyla would be a multi-billion dollar drug. The news... More
Immunogen (IMGN) Declines; Roche Reports Disappointing MARIANNE Trial Results
December 19, 2014 8:01 AM ESTImmunoGen, Inc.(NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche (OTC: RHHBY) has announced top-line results of its Phase III MARIANNE study.
The study evaluated three HER2-targeted regimens Kadcyla® (ado-trastuzumab emtansine) plus Perjeta® (pertuzumab), Kadcyla alone, and Herceptin® (trastuzumab) plus taxane chemotherapy in people with previously... More
